183 related articles for article (PubMed ID: 28940316)
1. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
Mason JM; Chalmers JR; Godec T; Nunn AJ; Kirtschig G; Wojnarowska F; Childs M; Whitham D; Schmidt E; Harman K; Walton S; Chapman A; Williams HC;
Br J Dermatol; 2018 Feb; 178(2):415-423. PubMed ID: 28940316
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
3. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial.
Mason JM; Thomas KS; Ormerod AD; Craig FE; Mitchell E; Norrie J; Williams HC;
Br J Dermatol; 2017 Dec; 177(6):1527-1536. PubMed ID: 28391619
[TBL] [Abstract][Full Text] [Related]
4. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
Williams HC; Wojnarowska F; Kirtschig G; Mason J; Godec TR; Schmidt E; Chalmers JR; Childs M; Walton S; Harman K; Chapman A; Whitham D; Nunn AJ;
Lancet; 2017 Apr; 389(10079):1630-1638. PubMed ID: 28279484
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Nunn AJ; Bratton DJ; Mason J; Foster KA; Whitham D; Williams HC;
Br J Dermatol; 2015 Jul; 173(1):227-34. PubMed ID: 25683592
[TBL] [Abstract][Full Text] [Related]
6. Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.
Finch AP; van Velzen P; Ter Riet G; Sterk PJ; Prins JM; Bosmans JE
Pharmacoeconomics; 2019 May; 37(5):689-699. PubMed ID: 30565022
[TBL] [Abstract][Full Text] [Related]
7. Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid.
Sach T
Br J Dermatol; 2018 Feb; 178(2):320-321. PubMed ID: 29441558
[No Abstract] [Full Text] [Related]
8. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.
McCrone P; Chisholm D; Knapp M; Hughes R; Comi G; Dalakas MC; Illa I; Kilindireas C; Nobile-Orazio E; Swan A; Van den Bergh P; Willison HJ;
Eur J Neurol; 2003 Nov; 10(6):687-94. PubMed ID: 14641514
[TBL] [Abstract][Full Text] [Related]
9. Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.
Holtsche MM; Goletz S; van Beek N; Zillikens D; Benoit S; Harman K; Walton S; English J; Sticherling M; Chapman A; Levell NJ; Groves R; Williams HC; König IR; Schmidt E;
Br J Dermatol; 2018 Oct; 179(4):918-924. PubMed ID: 29607480
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline, a Well-Tolerated, Economic, and Effective Alternative for the First-Line Treatment of Bullous Pemphigoid.
Morgado-Carrasco D; Riquelme-Mac Loughlin C; Fustà-Novell X; Iranzo P
Actas Dermosifiliogr (Engl Ed); 2018; 109(6):549-550. PubMed ID: 29175174
[No Abstract] [Full Text] [Related]
12. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
13. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
[TBL] [Abstract][Full Text] [Related]
14. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Facilitated Access to a Self-Management Website, Compared to Usual Care, for Patients With Type 2 Diabetes (HeLP-Diabetes): Randomized Controlled Trial.
Li J; Parrott S; Sweeting M; Farmer A; Ross J; Dack C; Pal K; Yardley L; Barnard M; Hudda M; Alkhaldi G; Murray E
J Med Internet Res; 2018 Jun; 20(6):e201. PubMed ID: 29884608
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
[TBL] [Abstract][Full Text] [Related]
17. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
[TBL] [Abstract][Full Text] [Related]
18. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.
Craig FF; Thomas KS; Mitchell EJ; Williams HC; Norrie J; Mason JM; Ormerod AD;
Trials; 2012 Apr; 13():51. PubMed ID: 22540770
[TBL] [Abstract][Full Text] [Related]
19. Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT.
Gohel MS; Heatley F; Liu X; Bradbury A; Bulbulia R; Cullum N; Epstein DM; Nyamekye I; Poskitt KR; Renton S; Warwick J; Davies AH
Health Technol Assess; 2019 May; 23(24):1-96. PubMed ID: 31140402
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility of first-line actinic keratosis treatments in Finland.
Soini EJ; Hallinen T; Sokka AL; Saarinen K
Adv Ther; 2015 May; 32(5):455-76. PubMed ID: 26006101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
